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Abstract
Tubulin-containing structures are important for many important cellular functions, 
including chromosome segregation during cell division, development and maintenance 
of cell shape, cell motility, and distribution of molecules on cell membranes. The rapid 
growth of cancer cells makes them very sensitive to the disruption of tubulin 
polymerization/depolymerization. Taxol (paclitaxel), a tubulin inhibitor approved by 
the FDA in 1992 for cancer treatment, is one of the most powerful chemotherapeutic 
agents. However, the low water solubility and drug resistance limits its clinical 
application. Various effort in drug discovery field focuses on more water soluble 
smaller molecular tubulin inhibitors. Our previous study led to the discovery of tubulin 
inhibitors with IC50s below 1nM to inhibit cancer cell proliferation, and these 
compounds have much small molecular weight than Taxol. In addition, our compounds 
showed promising in vivo anti-cancer activity as well. To further improve the 
druggable characteristics of our drug candidates, we focus on the ligand efficiency of 
these compounds in the current proposed study. A series of new analogs were designed 
and synthesized, and their structures were elucidated with NMR spectrum. Their anti­
cancer activity was determined with breast cancer cell lines. Several new compounds 
exhibited promising anti-cancer activity.
